Oncology (all articles)
RCT | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment.
12 Jul, 2022 | 11:51h | UTC
Commentary on Twitter
Updated results from the phase III ICON8 trial in 1,566 pts with newly diagnosed stage IC–IV epithelial ovarian, peritoneal or fallopian tube carcinoma reveal no statistically significant difference in OS with 3-weekly vs weekly carboplatin & paclitaxel: https://t.co/czgH7uGxjt
— NatureRevClinOncol (@NatRevClinOncol) June 15, 2022
Single-arm Study | Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation.
11 Jul, 2022 | 11:56h | UTCExtended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary: Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers — Trial’s 6-month rate of 6% was superior to historical control – MedPage Today (free registration required)
Commentary on Twitter
This single-arm objective performance criteria trial indicated excellent efficacy and safety profile of the second-generation high-frequency irreversible electroporation as primary treatment for localized prostate cancer. https://t.co/FheqcxJeA5
— JAMA Surgery (@JAMASurgery) July 7, 2022
Cohort Study | Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels.
11 Jul, 2022 | 11:53h | UTCAuthor Interview: High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade – JAMA
Commentaries:
Tumor mutational burden ‘valuable biomarker’ for ICI response in NSCLC – medwire News
Commentary on Twitter
Very high levels of tumor mutational burden (TMB) are associated with benefit from #immunotherapy in NSCLC across PD-L1 expression levels and increased CD8+ T cells infiltration. https://t.co/qbq00ZzjFO #LCSM
— JAMA Oncology (@JAMAOnc) June 22, 2022
Long-term analysis of a Phase 2 RCT | Fulvestrant plus capivasertib vs. placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive, HER2-negative breast cancer.
11 Jul, 2022 | 11:48h | UTCNews Release: New phase of breast cancer drug trial provides fresh hope for patients with incurable disease – Cardiff University
M-A | Associations of thiazide use with skin cancers.
8 Jul, 2022 | 11:55h | UTCAssociations of thiazide use with skin cancers: a systematic review and meta-analysis – BMC Medicine
Related:
Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma – JAMA Internal Medicine
RCT | Cabozantinib plus atezolizumab vs. sorafenib for advanced hepatocellular carcinoma.
8 Jul, 2022 | 11:41h | UTCInvited Commentary: Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy – The Lancet Oncology (free registration required)
Commentary on Twitter
In the phase III COSMIC-312 trial in 837 pts with advanced-stage HCC, mPFS was 6.8 vs 4.2 months (HR 0.63; P=.0012) & mOS was 15.4 vs 15.5 months (HR 0.90; P=.44) with cabozantinib+atezolizumab vs sorafenib; mPFS with cabozantinib alone was 5.8 months: https://t.co/eiZEqSxLAr
— NatureRevClinOncol (@NatRevClinOncol) July 6, 2022
RCT | Efficacy and safety of a Pegasparaginase-based chemotherapy regimen vs. an L-asparaginase–based chemotherapy regimen for newly diagnosed advanced extranodal Natural Killer/T-Cell Lymphoma.
8 Jul, 2022 | 11:21h | UTCEfficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: De-escalating Chemotherapy for Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Step Toward Improved Treatment of a Rare Virus-Associated Cancer – JAMA Oncology (free for a limited period)
See also: Visual Abstract
Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children.
8 Jul, 2022 | 11:20h | UTC
Commentaries on Twitter
A multigene classifier reveals that malignant pediatric thyroid nodules have a unique molecular landscape vs those in adults. The classifier had a sensitivity of 96% & specificity of 78% for cancer detection & might reduce the need for diagnostic surgery: https://t.co/hdsPjGe9IR
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Pediatric thyroid cancer is on the rise. Its genomic landscape is unique; but, this retrospective case series shows that it may still be amenable to molecular classification—potentially decreasing diagnostic surgery & opening avenues for targeted therapy. https://t.co/KiYMsB1qGM
— JAMA Oncology (@JAMAOnc) June 10, 2022
RCT | Orteronel for metastatic hormone-sensitive prostate cancer.
8 Jul, 2022 | 11:18h | UTCCommentary: Orteronel Misses Goal in Metastatic Hormone-Sensitive Prostate Cancer – HealthDay
Commentary on Twitter
⛔ SWOG-1216: Orteronel did not improve overall survival for metastatic hormone sensitive #ProstateCancer ➡️ https://t.co/aejFNEb7bM #JCO #PCSM @theNCI @SWOG @neerajaiims @shilpaonc pic.twitter.com/LP5oHQqSIg
— Journal of Clinical Oncology (@JCO_ASCO) May 6, 2022
M-A | Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment.
7 Jul, 2022 | 12:17h | UTC
M-A | Adjuvant treatments of adult melanoma.
7 Jul, 2022 | 12:12h | UTC
Consensus Statements | Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in patients with prostate cancer and with respect to [177Lu] Lu-PSMA radioligand therapy.
6 Jul, 2022 | 11:39h | UTCPodcast | Overview of checkpoint inhibitors for general practitioners.
6 Jul, 2022 | 11:29h | UTC#342 Checkpoint Inhibitors – The Curbsiders
Network M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.
6 Jul, 2022 | 11:09h | UTCHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022
The multicenter cancer of pancreas screening study: impact on stage and survival.
5 Jul, 2022 | 11:46h | UTC
Commentary on Twitter
👀 The Cancer of Pancreas Screening (CAPS) program achieves early #PancreaticCancer detection and long-term survival with surveillance ➡️ https://t.co/flqUtSvkcg #JCO #pancSM @mggoggins pic.twitter.com/wj6DMXclVC
— Journal of Clinical Oncology (@JCO_ASCO) June 30, 2022
M-A | Risk factors of clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy.
5 Jul, 2022 | 11:32h | UTCGuideline | Malignancy risk stratification for solitary pulmonary nodule.
4 Jul, 2022 | 12:33h | UTCRCT | Effect of levofloxacin on the efficacy and adverse events in intravesical Bacillus Calmette-Guerin treatment for bladder cancer.
4 Jul, 2022 | 12:19h | UTCRCT | CT vs. [18F]FDG-PET-CT for persistent or recurrent neutropenic fever in high-risk patients.
4 Jul, 2022 | 12:21h | UTC[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: [18F]FDG-PET-CT resulted in more frequent antimicrobial rationalisation than CT in patients w/ haem diseases & persistent/recurrent high-risk neutropenic fever after chemotherapy. Results of the ph3 RCT PIPPIN #radonc #hemonc https://t.co/isOPFZVVpY pic.twitter.com/PVd8yFy7Ck
— The Lancet Haematology (@TheLancetHaem) June 29, 2022
Phase 1 single-arm study | Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma.
4 Jul, 2022 | 12:08h | UTCOncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Oncolytic Virus Infusion Promising as Brain-Stem Glioma Treatment — Phase I trial shows encouraging OS in children with diffuse intrinsic pontine glioma – MedPage Today (free registration required)
2022 Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
1 Jul, 2022 | 11:50h | UTCRelated:
UEG and EAES rapid guideline on transanal total mesorectal excision for rectal cancer.
1 Jul, 2022 | 11:33h | UTC
RCT: Oxaliplatin (3 months vs. 6 months) with 6 months of Fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer.
1 Jul, 2022 | 10:59h | UTC
RCT: Effect of a community health worker intervention on acute care use, advance care planning, and patient-reported outcomes among adults with advanced stages of cancer.
1 Jul, 2022 | 10:58h | UTCEffect of a Community Health Worker Intervention on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes Among Adults With Advanced Stages of Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
See also: Visual Abstract
RCT: The effect of enhanced recovery after minimally invasive esophagectomy.
1 Jul, 2022 | 10:56h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Visual abstract: ASO Visual Abstract: Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery—ERAS and Esophagectomy
Enhanced recovery after surgery (ERAS) programs for esophagectomy – Journal of Thoracic Disease